Three boys. One dose level. About six months of follow-up. That is the full dataset behind Ractigen Therapeutics’ first look at its Duchenne drug RAG-18 in people, and it should frame everything that follows.

The privately held Chinese biotech presented the Phase 1 results on October 3 at the World Muscle Society’s 31st Annual Congress (WMS 2026) in Hiroshima, Japan, according to a company press release issued that day. The main finding: muscle biopsies showed more utrophin, a backup protein the drug is built to switch on, after about four months of treatment.

If that holds up, it matters. A utrophin drug could in principle help any boy with Duchenne muscular dystrophy (DMD), whatever his mutation. Most targeted DMD drugs available today cover only specific ones.

What RAG-18 Is Designed to Do

DMD is a rare inherited disease that mostly strikes boys. A faulty DMD gene leaves muscle without dystrophin, the protein that keeps fibers from tearing during contraction. Muscle wastes away. Walking goes first. Breathing and heart function follow.

Utrophin is dystrophin’s close structural relative. The body makes plenty before birth, then largely shuts it off. RAG-18 is a small activating RNA (saRNA), a short double strand of RNA that targets regulatory regions of the UTRN gene so cells make more of their own utrophin. Ractigen calls the approach RNA activation, or RNAa. Most approved RNA drugs do the reverse and silence genes.

The drug is given as a monthly intravenous (IV) infusion. No viral vector, no permanent DNA editing. The FDA granted it Orphan Drug and Rare Pediatric Disease designations in 2024. Neither is an approval, and neither says anything about whether the drug works.

What the Biopsies Showed

The open-label, dose-escalation study (NCT07282652) enrolls boys aged 4 to 15 who can still walk. Cohort 1 received 15 mg once a month, and the presentation covered data through Day 169.

Paired muscle biopsies at Day 113 showed a 3.5- to 5.3-fold increase in utrophin signal at the sarcolemma, the muscle fiber’s outer membrane, in mature fibers versus pre-treatment levels. Regenerating fibers showed a 4.1- to 4.7-fold rise. Staining placed the protein where it belongs.

Tissue measures moved the same way. Average fiber size rose 5% to 15%, and fat fraction fell 3% to 10%. MRI T2 relaxation time, which the company reads as a gauge of swelling and inflammation, dropped up to 11.6% by Day 169.

Safety looked clean in this tiny group: no dose-limiting toxicities, no serious adverse events, nothing rated Grade 3 or higher. All side effects were mild to moderate and resolved on their own.

Function Is a Mixed Bag

The release talks up “positive trajectories” on function. The individual numbers are messier.

All three boys lost 3 points on the North Star Ambulatory Assessment (NSAA), a standard 17-item motor scale used in DMD trials. On the six-minute walk test, a 6.8-year-old gained 36.5 meters and a 12.7-year-old held steady (down 1.0 meter) with a faster four-stair climb. The third boy, age 7.3, walked 62.5 meters less.

Lung readings rose in all three, with percent-predicted forced vital capacity up 2.8% to 41.0% over 24 weeks. A 41% jump in one child is big. Spirometry in young kids depends on effort and technique, so swings like that are hard to read. Heart function stayed normal.

There is no placebo arm. With three patients, none of these changes can be pinned on the drug, and the trial treats efficacy as exploratory.

Checking the “First” Claim

Ractigen calls this the first clinical proof-of-mechanism for RNAa in a human monogenic disease, meaning one caused by a single faulty gene. Those qualifiers carry weight. RAG-18 is not the first saRNA given to people. London-based MiNA Therapeutics began dosing its saRNA, MTL-CEBPA, in liver cancer in 2016, and a 2020 Phase 1 paper in Clinical Cancer Research called it the first saRNA in clinical trials. The narrower claim looks defensible. RNAa in humans is about a decade old.

Utrophin’s Rough History

Utrophin has let the field down before. Summit Therapeutics’ ezutromid, an oral small molecule meant to sustain utrophin, posted encouraging 24-week signals in its Phase 2 PhaseOut DMD trial, including lower MRI T2 readings. They didn’t last. At 48 weeks the drug missed its primary and secondary endpoints, Summit dropped it in June 2018, and its shares fell about 80%.

Yes, that Summit (Nasdaq: SMMT), now known for the cancer drug ivonescimab. The two drugs work very differently, so this is no direct read-across. Still, early biopsy and MRI wins in DMD tend to fade.

A Crowded, Shifting Field

Sarepta Therapeutics’ (Nasdaq: SRPT) gene therapy Elevidys is now limited to boys 4 and older who can walk, with a boxed warning for serious liver injury after deaths from acute liver failure in non-ambulatory patients. Italfarmaco’s Duvyzat (givinostat), approved in March 2024, was the first nonsteroidal drug cleared for all genetic variants of DMD, in patients 6 and up.

Exon-skipping drugs, which help cells read past specific mutations, are the busiest corner. Four hold FDA accelerated approval. Novartis (NYSE: NVS) unit Avidity Biosciences filed for approval of del-zota in June 2026, and Dyne Therapeutics (Nasdaq: DYN) began a Phase 3 trial of z-rostudirsen in May. Each covers only certain mutations. That’s the gap utrophin is meant to fill.

What the Release Doesn’t Say

Utrophin gains are given only as fold-change, not as a share of normal levels, so there’s no way to judge their absolute size. The release doesn’t say whether the boys were on corticosteroids, standard DMD care that can sway function scores. It offers no timeline for Cohort 2 data or a Phase 2 trial, and nothing on U.S. trial plans despite the FDA designations.

It also skips some context. Ractigen’s December 2025 announcement called this an investigator-initiated trial at Peking Union Medical College Hospital. And after raising more than $31 million in July 2026, the company said part of the money would go toward preparing an investigational new drug (IND) filing for RAG-18. There is no stock ticker.

Cohort 2, at 30 mg monthly, is fully enrolled. That’s the next test. Time is the one after it.

Sources

• Ractigen Therapeutics: Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy, PRNewswire, October 3, 2026. Primary source release.
• Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, PRNewswire, December 12, 2025. Cited for the study’s investigator-initiated status at Peking Union Medical College Hospital and the 2024 timing of RAG-18’s FDA designations.
• Ractigen Therapeutics Raises Over $31M in Funding, FinSMEs, July 2026. Cited for Ractigen’s private status, latest financing, and stated plan to prepare an IND filing for RAG-18.
• MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human Phase I Trial, Clinical Cancer Research (2020), via PubMed. Cited to check Ractigen’s “first” claim against the earlier clinical history of saRNA drugs.
• Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint, GlobeNewswire, June 27, 2018. Cited for the failure and discontinuation of the utrophin modulator ezutromid.
• Summit Turns From DMD After Trial Miss, BioPharma Dive. Cited for ezutromid’s 24-week interim signals that were not sustained at 48 weeks, and the resulting share-price drop.
• FDA Approves New Safety Warning and Revised Indication for ELEVIDYS, Parent Project Muscular Dystrophy. Cited for Elevidys’s current ambulatory-only label and boxed warning.
• FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy, U.S. Food and Drug Administration, March 21, 2024. Cited for the approval of Duvyzat (givinostat).
• After 10 Years on the Market, Exon-Skipping Therapies Have ‘Revolutionized’ DMD Treatment, Rare Disease Advisor, September 3, 2026. Cited for Avidity’s del-zota filing and Dyne’s Phase 3 FORZETTO trial.
• Novartis Successfully Completes Acquisition of Avidity Biosciences, Novartis, February 27, 2026. Cited for Avidity’s current ownership.

Editorial Disclosure

This article reports on first-in-human clinical trial data for RAG-18 presented at the 31st Annual Congress of the World Muscle Society (WMS 2026), based on a press release issued by Ractigen Therapeutics on October 3, 2026. Ractigen Therapeutics is a privately held company with no publicly traded securities. Securities and corporate structures referenced for competitive context: Sarepta Therapeutics, Inc. (Nasdaq: SRPT), Dyne Therapeutics, Inc. (Nasdaq: DYN), Summit Therapeutics Inc. (Nasdaq: SMMT), and Novartis AG (NYSE: NVS, via its wholly owned subsidiary Avidity Biosciences, Inc.), along with privately held Italfarmaco S.p.A. and MiNA Therapeutics. Information on competing therapies, the history of ezutromid, earlier saRNA clinical trials, the study’s investigator-initiated status, and Ractigen’s financing was drawn from independent sources cited above, since the original release did not address these points. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Ractigen Therapeutics or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding future clinical results, higher-dose cohort outcomes, regulatory filings, development timelines, and the potential of RAG-18 or RNA activation as a treatment approach are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual outcomes may differ materially. Early results from very small, uncontrolled studies often fail to predict later findings. Drug development is subject to high rates of clinical failure, regulatory rejection, and market competition. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; RAG-18 is an investigational therapy that has not been approved by the FDA or any other regulator, and patients, families, and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.